Blueprint Medicines's market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; Blueprint Medicines is scheduled to report earnings on May 2, 2024, and the estimated EPS forecast is $-1.67. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 71.96M	$ 56.57M	$ 39.88M	$ 63.29M	$ -1.38M
Gross Profit	$ 71.70M	$ 53.78M	$ 56.48M	$ -4.47M	$ -6.72M
EBIT	$ -105.69M	$ -129.71M	$ -128.61M	$ -129.04M	$ -148.37M
EBITDA	$ -101.81M	$ -124.53M	$ -122.77M	$ -123.15M	$ -139.20M
Net Income Common Stockholders	$ -110.92M	$ -130.17M	$ -132.79M	$ -129.56M	$ -158.65M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 710.64M	$ 712.98M	$ 722.63M	$ 822.16M	$ 944.99M
Total Assets	$ 1.05B	$ 1.11B	$ 1.11B	$ 1.22B	$ 1.35B
Total Debt	$ 774.12M	$ 774.18M	$ 675.68M	$ 674.93M	$ 672.78M
Net Debt	$ 63.48M	$ 61.19M	$ -46.95M	$ -147.23M	$ -272.21M
Total Liabilities	$ 918.64M	$ 902.69M	$ 795.32M	$ 806.07M	$ 1.35B
Stockholders Equity	$ 130.61M	$ 202.61M	$ 311.13M	$ 414.30M	$ 514.68M
Cash Flow	-
Free Cash Flow	$ -83.60M	$ -110.73M	$ -133.03M	$ -125.55M	$ -122.89M
Operating Cash Flow	$ -78.93M	$ -104.48M	$ -130.47M	$ -122.96M	$ -121.41M
Investing Cash Flow	$ 78.77M	$ -9.59M	$ 32.07M	$ 172.79M	$ -53.23M
Financing Cash Flow	$ 15.53M	$ 98.40M	$ 5.30M	-	$ 2.49M

Currency in USD

Blueprint Medicines Earnings and Revenue History

Income Statement >

Blueprint Medicines Debt to Assets

Balance Sheet >

Blueprint Medicines Cash Flow

Cash Flow >

Blueprint Medicines Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing